Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Aptahem AB (publ) is a clinical-stage biotechnology company dedicated to creating aptamer-based pharmaceuticals aimed at treating acute, life-threatening medical conditions. Its flagship drug candidate, Apta-1, is currently in preclinical development, designed to reduce the mortality rate in sepsis patients by combating organ and tissue damage. The company has established partnerships with several academic institutions, notably through a consortium comprising Örebro University, Seattle Children's Research Institute, and University Health Network. Founded in 2014, Aptahem AB (publ) operates from its headquarters in Malmö, Sweden.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.